Market Intelligence, Clinical Progress, and High-Purity Reagents for Neutropenia, Oncology, and Inflammation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for G-CSFR/CSF3R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | CSF3R ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CSF3R Products |
| Antigen (Oncogenic Mutants) | CSF3R-T618I / T640N Mutant Proteins Sequence-verified oncogenic variants for selectivity screening. Theoretical MW confirmed. |
View CSF3R Products |
| Gene Delivery | CSF3R Promise-ORF / Lentivirus Full-length ORF with puromycin selection for stable Ba/F3 or 32D cell line construction. |
View CSF3R Products |
| Benchmark Ab | Anti-CSF3R Neutralizing Antibody Recombinant positive control for receptor blockade assays. |
View CSF3R Products |
| Validator | CSF3R siRNA Set For knockdown verification and specificity controls. |
View CSF3R Products |
| Ligand Partner | CSF3 (G-CSF) Native ligand for competition binding and functional activation assays. |
View CSF3 Products |
| Homologue Counter-Screen | CSF1R (M-CSFR) Close family member for specificity testing against related colony-stimulating factor receptors. |
View CSF1R Products |
| Pathway Associate | CXCR4 Synergistic axis in hematopoietic stem cell mobilization and leukemia microenvironment. |
View CXCR4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs. Wild-Type Selectivity (AML Safety) | Purified CSF3R-T618I & CSF3R-T640N Mutant Proteins alongside WT, all Sequence Verified by Mass Spec for selective binding assays. |
| Cross-species Toxicology (Cyno/Mouse) | Human/Mouse/Cynomolgus CSF3R ECD orthologs available with >95% purity, Endotoxin Controlled. |
| ADC Internalization Efficiency | High-purity ECD-Fc maintains native conformation; suitable for flow cytometry-based internalization quantification. |
| Subfamily Selectivity (CSF1R/IL-3R) | Homolog panel proteins (CSF1R, IL3RA) strictly verified by sequencing for counter-screening. |
| False Positives in Binding | Validated CSF3R siRNA and neutralizing antibody controls included for assay specificity verification. |
Live G-CSFR/CSF3R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic paradigm for CSF3R is shifting from ligand supplementation (G-CSF analogs) to direct receptor modulation. While traditional G-CSF therapies dominate the neutropenia market, the next wave targets oncogenic CSF3R mutations (T618I, T640N) driving severe congenital neutropenia (SCN) progression to AML. As first-generation mutation-specific inhibitors and antibody-drug conjugates (ADCs) enter Phase I/II, differentiation will depend on selectivity profiles that spare normal hematopoiesis while eradicating malignant clones. The race for G-CSFR therapeutics is intensifying, with major players shifting focus from traditional recombinant agonists to long-acting variants and targeted antagonists for chronic inflammatory conditions.
Competitive Modality & Indication Snapshot
| Modality | Development Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Targeting CSF3R-expressing AML blasts | Acute Myeloid Leukemia (AML) | Internalization Assay (Need high-purity ECD-Fc for binding) & Mutant vs WT Selectivity Panel |
| Small Molecule Inhibitor | Selective inhibition of T618I signaling | SCN-derived AML, MDS | Mutant vs WT Protein Binding (SPR/Biacore) with Sequence-verified antigens |
| Neutralizing Antibody | Autoimmune neutropenia | Autoimmune/Idiopathic Neutropenia | Receptor Blockade Assay using Full-length Lentivirus-stable cell lines |
| CAR-T/NK Cell Therapy | CSF3R-directed cellular immunotherapy | Relapsed/Refractory AML | Cell surface antigen quantification using calibrated ECD standards |
Molecular Differentiation & Assay Strategy
1. Mutant Selectivity (Mutant vs WT)
T618I mutation in the membrane-proximal domain causes ligand-independent dimerization and signaling. Inhibitors must recognize mutation-induced conformational changes.
- Assay Strategy: SPR/BLI with WT and T618I/T640N mutant proteins; cell proliferation inhibition using Ba/F3-CSF3R-WT vs Ba/F3-CSF3R-T618I stable cell lines.
2. Internalization Efficiency (ADC Development)
CSF3R internalization kinetics determine ADC therapeutic window. Chronic G-CSF stimulation may downregulate receptor internalization.
- Assay Strategy: Flow cytometry with Alexa Fluor 488-labeled CSF3R-ECD-Fc; pH-sensitive binding assay for endosomal release.
3. Cross-species Reactivity
Preclinical toxicology requires cross-reactivity with cynomolgus and mouse CSF3R.
- Assay Strategy: Multi-species ortholog protein panel (Human, Cyno, Mouse); counter-screening with CSF1R to avoid macrophage toxicity.